Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.55 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | COMT | P21964 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | FABP3 | P05413 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5517575 | 0.90 | KDM4E (0.53) | TYRDOHHKDM4ECOMTCA12 | |
| SCHEMBL9704932 | 0.88 | TYR (0.51) | TYRDOHHKDM4ECOMTCA12 | |
| SCHEMBL9700040 | 0.81 | TYR (0.58) | TYRDOHHKDM4ECOMTCA12 | |
| SCHEMBL8102332 | 0.78 | DOHH (0.54) | TYRDOHHKDM4ECOMTCA12 | |
| SCHEMBL10924548 | 0.78 | TYR (0.50) | TYRDOHHKDM4ECOMTCA12 | |
| SCHEMBL17128963 | 0.78 | DOHH (0.50) | TYRDOHHKDM4ECOMTCA12 | |
| SCHEMBL8108765 | 0.76 | MAOB (0.43) | TYRDOHHKDM4EMAOBMAPT | |
| SCHEMBL11908469 | 0.74 | ALDH1A1 (0.46) | KDM4EEGLN3ALDH1A1PKMMAPT | |
| SCHEMBL16088174 | 0.74 | NPC1 (0.47) | TYRDOHHKDM4ECA12CA1 | |
| SCHEMBL7640934 | 0.73 | TYR (0.53) | TYRDOHHKDM4ECOMTCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| WO-1992012131-A1 | 3-HYDROXYPYRIDIN-4-ONE DERIVATIVES AS PHARMACEUTICAL COMPOSITIONS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1992-07-23 | — | — | WO | claimed |
| EP-0494754-A1 | 3-hydroxypyridin-4-one derivatives as pharmaceutical compositions | BRITISH TECHNOLOGY GROUP LTD (GB) | 1992-07-15 | — | — | EP | claimed |
| EP-0145228-A1 | Pharmaceutical compositions | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1985-06-19 | — | — | EP | claimed |
| US-9580610-B2 | Aluminium oxide pastes and process for the use thereof | MERCK PATENT GMBH (DE) | 2017-02-28 | — | — | US | disclosed |
| US-20140000481-A1 | ALUMINIUM OXIDE PASTES AND PROCESS FOR THE USE THEREOF | MERCK PATENT GMBH (DE) | 2014-01-02 | — | — | US | disclosed |
| US-20130334454-A1 | FORMULATIONS OF PRINTABLE ALUMINIUM OXIDE INKS | MERCK PATENT GMBH (DE) | 2013-12-19 | — | — | US | disclosed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | disclosed |
| US-6555663-B1 | Pharmaceuticals which are activated intracellularly by reaction with cellular electron carriers or free radicals to cause release of a free and active drug molecule | MILLS RANDELL LEE (US) | 2003-04-29 | — | — | US | disclosed |
| EP-0414730-B1 | Chemical Compounds and pharmaceutical compositions capable of releasing a drug | MILLS RANDELL L (US) | 1999-12-15 | — | — | EP | disclosed |
| US-5773592-A | COMPRISES A CHEMILUMINESCENT MOIETY, A PHOTOCHROMIC MOIETY AND A BIOLOGICALLY ACTIVE AGENT CAPABLE OF BEING RELEASED | MILLS RANDELL LEE (US) | 1998-06-30 | — | — | US | disclosed |
| US-5428163-A | Luminides; chemiluminescence; redox system, releasing free drug | MILLS RANDELL L (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0414730-A4 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | — | 1993-06-16 | — | — | EP | disclosed |
| EP-0414730-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | Mills, Randell L. (US) | 1991-03-06 | — | — | EP | disclosed |
| US-4894455-A | Pharmaceutically active zinc complexes | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1990-01-16 | — | — | US | disclosed |
| WO-1989009833-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | MILLS RANDELL L (US) | 1989-10-19 | — | — | WO | disclosed |
| US-4665064-A | IN BLOOD; ZINC CHELATE | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1987-05-12 | — | — | US | disclosed |
| EP-0145228-A1 | Pharmaceutical compositions | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | TYR 3316/4885DOHH 464/4885KDM4E 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.